Secondary Logo

Institutional members access full text with Ovid®

Long-acting injectable second-generation antipsychotics in first-episode psychosis

a narrative review

Salgueiro, Monikaa; Segarra, Rafaela,b,c

International Clinical Psychopharmacology: March 2019 - Volume 34 - Issue 2 - p 51–56
doi: 10.1097/YIC.0000000000000249

Long-acting injectable (LAI) antipsychotics could be a favorable option of treatment and have some advantages over oral medications. The aim of this study was to review the published data on the use of LAI formulation of second-generation antipsychotics (SGA) in first-episode psychosis (FEP). Using PubMed and Scopus databases, we performed a systematic literature search of articles published between 1 January 2000 and 30 April 2018, that reported clinical trials on the use of LAI SGAs in patients with FEP. Seventy-seven articles were considered eligible and full-text revised. Five studies fulfilled the inclusion criteria and evaluated the effect of LAI risperidone in FEP patients. Treatment with LAI SGAs was well accepted, and the majority of FEP patients agreed to change from an oral to an injectable formulation. At the 12-month follow-up, between 68 and 95% of FEP patients treated with LAI risperidone showed a good clinical response and 64% achieved remission of symptoms for at least 24 months of follow-up. Treatment with LAI SGAs can offer significant advantages over oral antipsychotics to FEP patients, especially to improve the adherence to medication and prevent the worsening of symptoms, the relapse, and rehospitalization associated with the discontinuation of treatment.

aDepartment of Psychyatry, Cruces University Hospital, Osakidetza-Basque Health System, BioCruces Health Research Institute, Barakaldo

bDepartment of Neurosciences, School of Medicine and Nursery, University of the Basque Country (UPV/EHU), Leioa

cCentro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain

Correspondence to Monika Salgueiro, PhD, Department of Psychiatry, BioCruces Health Research Institute-HRi, Cruces University Hospital, Plaza Cruces 12, 48903 Barakaldo (Bizkaia), Spain Tel: +34 946 006 004; fax: +34 946 006 294; e-mail:

Received August 27, 2018

Accepted November 19, 2018

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.